Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Innate Immun ; : 1-18, 2022 Jun 10.
Article in English | MEDLINE | ID: mdl-35691281

ABSTRACT

Immune reactions after trauma are characterized by immediate activation of innate immunity and simultaneously downregulation of adaptive immunity leading to a misbalanced immunohomeostasis and immunosuppression of the injured host. Therefore, the susceptibility to secondary infections is strongly increased after trauma. Immune responses are regulated by a network of immune cells influencing each other and at the same time modifying their functions dependent on the inflammatory environment. Although myeloid-derived suppressor cells (MDSCs) are initially described as T-cell suppressors, their immunomodulatory capacity after trauma is mostly undefined. Therefore, in vitro-generated MDSCs were adoptively transferred into mice after blunt chest trauma (TxT). A single MDSC treatment-induced splenic T-cell expansion decreased apoptosis sensitivity and improved proliferation in the absence of T-cell exhaustion until 2 weeks after trauma. MDSC treatment had a long-lasting effect on the genomic landscape of CD4+ T cells by upregulating primarily Th2-associated genes. Remarkably, immune-activating functions of MDSCs supported the ability of TxT mice to respond to post-traumatic secondary antigen challenge. Secondary insults were mimicked by immunizing MDSC-treated TxT mice with ovalbumin (OVA), followed by OVA restimulation in vitro. MDSC treatment significantly increased the frequency of OVA-specific T cells, enhanced their Th1/Th2 cytokine expression, and induced upregulation of cytolytic molecules finally improving OVA-specific cytotoxicity. Overall, we could show that therapeutic MDSC treatment after TxT improves post-traumatic T-cell functions, which might enable the traumatic host to counterbalance trauma-induced immunoparalysis.

2.
J Immunol ; 171(3): 1172-82, 2003 Aug 01.
Article in English | MEDLINE | ID: mdl-12874203

ABSTRACT

Elimination of T cells during an immune response is mediated by activation-induced cell death (AICD) and CD95-mediated apoptosis. Chronic graft-vs-host disease and T cell-mediated autoimmune diseases are caused by the persistence of activated T cells that escaped tolerance induction by deletion or silencing. To mimic the in vivo situation of long-term activated T cells, we generated an in vitro system using HLA-A1-specific T cells, weekly restimulated by Ag. While short-term activated T cells (two to five rounds of stimulation) were CD95 sensitive and susceptible to AICD, T cells stimulated more than eight times acquired constitutive CD95 resistance and exhibited reduced AICD. Phenotypically, these long-term activated T cells could be identified as effector/memory T cells. The expression of the proforms of the CD95 receptor initiator caspases, caspase-8 and -10, and the effector caspase-3 was strongly decreased in these cells, and only active caspase fragments were detected. In contrast to short-term activated T cells, constitutive CD95 receptor clustering was observed on the cell surface, and caspase-8 was bound to the CD95 receptor in the absence of receptor triggering. After further cross-linking of CD95, additional formation of the death-inducing signaling complex (DISC) was strongly impaired. Reduced DISC formation in long-term activated T cells was associated with the loss of PTEN expression and the increased phosphorylation of protein kinase B. Inhibitors of phosphoinositol 3-kinase restored CD95 sensitivity and DISC formation in long-term activated T cells. These data suggest that defective CD95 signaling in effector/memory T cells may contribute to the apoptosis resistance toward physiological stimuli in T cells mediating tissue destruction in vivo.


Subject(s)
Apoptosis/immunology , Caspases/metabolism , Intracellular Signaling Peptides and Proteins , Lymphocyte Activation/immunology , Proto-Oncogene Proteins , Receptors, Tumor Necrosis Factor/metabolism , Signal Transduction/immunology , T-Lymphocyte Subsets/enzymology , T-Lymphocyte Subsets/immunology , fas Receptor/physiology , CASP8 and FADD-Like Apoptosis Regulating Protein , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Carrier Proteins/biosynthesis , Carrier Proteins/physiology , Caspase Inhibitors , Cell Death/immunology , Cell Line , Cell Line, Transformed , Death Domain Receptor Signaling Adaptor Proteins , Down-Regulation/immunology , Enzyme Activation/immunology , Epitopes, T-Lymphocyte/immunology , Fas Ligand Protein , HLA-A1 Antigen/immunology , Humans , Immunity, Innate , Immunologic Memory , Immunophenotyping , Inhibitor of Apoptosis Proteins , Ligands , Membrane Glycoproteins/analysis , PTEN Phosphohydrolase , Phosphatidylinositol 3-Kinases/metabolism , Phosphoric Monoester Hydrolases/antagonists & inhibitors , Phosphoric Monoester Hydrolases/biosynthesis , Phosphorylation , Protein Biosynthesis , Protein Serine-Threonine Kinases/metabolism , Proteins/physiology , Proto-Oncogene Proteins c-akt , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/metabolism , Time Factors , Tumor Suppressor Proteins/antagonists & inhibitors , Tumor Suppressor Proteins/biosynthesis , Up-Regulation/immunology , X-Linked Inhibitor of Apoptosis Protein , fas Receptor/analysis , fas Receptor/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL